Feb 13 (Reuters) - Aeterna Zentaris Inc AEZ.TO
* Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm)
* FDA has agreed to consider company's conclusions during a type a meeting
* Co concluded that macrilen demonstrated performance supportive of achieving registration with U.S. Food and drug administration
* Aeterna Zentaris says co-primary endpoint "negative agreement" with itt, which is considered as more relevant endpoint, was met
* Says co-primary endpoint "positive agreement" with itt was not met Source text for Eikon: ID:nBw5fhdjXa Further company coverage: AEZ.TO